Kenneth J. Kelley, Director at HALOZYME THERAPEUTICS, INC. (HALO), bought 105,258 shares at $14.19 ($1.5M) on 2020-03-19, disclosed to the SEC on 2020-03-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.19 | 17,543 | $249K | 16.6% |
| 2 | $14.19 | 17,543 | $249K | 16.6% |
| 3 | $14.24 | 17,543 | $250K | 16.7% |
| 4 | $14.24 | 17,543 | $250K | 16.7% |
| 5 | $14.25 | 17,543 | $250K | 16.7% |
| 6 | $14.25 | 17,543 |
| $250K |
| 16.7% |
| Total | $14.23 avg | 105,258 | $1.5M | 100% |
| Filing → |
| HALO | SELL | 2021-02-01 | $469K | — | Filing → |
| HALO | SELL | 2021-01-04 | $417K | — | Filing → |
| HALO | SELL | 2020-12-07 | $1.4M | — | Filing → |